Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Statistical Methods for Analyzing Epidemiological Data01:25

Statistical Methods for Analyzing Epidemiological Data

310
Epidemiological data primarily involves information on specific populations' occurrence, distribution, and determinants of health and diseases. This data is crucial for understanding disease patterns and impacts, aiding public health decision-making and disease prevention strategies. The analysis of epidemiological data employs various statistical methods to interpret health-related data effectively. Here are some commonly used methods:
310
Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Upper-Extremity Deep Vein Thrombosis in Cancer: Beyond a Catheter-Related Complication.

JACC. CardioOncology·2026
Same author

Reasons for referral to a social prescribing program through the COVID-19 pandemic and associated factors: a cross-sectional study in Portugal.

Frontiers in public health·2026
Same author

Survival and mortality predictors among children living with HIV initiating antiretroviral therapy in Angola: a retrospective cohort study.

BMC public health·2026
Same author

Factors associated with the recurrence of intermittent exotropia and reoperations in the long term.

Annals of medicine·2026
Same author

NeoProspect HER2-low: Response and Prognosis After Neoadjuvant Treatment in Patients with HER2-low Breast Cancer.

Cureus·2026
Same author

Rising burden of second primary lung cancers: from survivorship to secondary prevention.

Thorax·2026

Related Experiment Video

Updated: Jun 9, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K

Current Evidence for a Lung Cancer Screening Program.

Teresa Guerreiro1, Pedro Aguiar1,2, António Araújo3,4

  • 1NOVA National School of Public Health, NOVA University of Lisbon, Lisbon, Portugal.

Portuguese Journal of Public Health
|October 29, 2024
PubMed
Summary
This summary is machine-generated.

Lung cancer screening using low-dose computed tomography (LDCT) effectively reduces mortality in high-risk individuals. Further optimization and new biomarkers can enhance early detection and improve outcomes.

Keywords:
Current evidenceLung cancerScreening

More Related Videos

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules
06:03

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules

Published on: May 23, 2015

22.3K
Lung Tumor Cell Recruitment Assay
04:28

Lung Tumor Cell Recruitment Assay

Published on: February 26, 2019

5.3K

Related Experiment Videos

Last Updated: Jun 9, 2025

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
08:14

MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening

Published on: October 26, 2017

15.6K
Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules
06:03

Use of Electromagnetic Navigational Transthoracic Needle Aspiration E-TTNA for Sampling of Lung Nodules

Published on: May 23, 2015

22.3K
Lung Tumor Cell Recruitment Assay
04:28

Lung Tumor Cell Recruitment Assay

Published on: February 26, 2019

5.3K

Area of Science:

  • Pulmonology
  • Oncology
  • Radiology

Background:

  • Lung cancer remains highly lethal, especially when diagnosed late.
  • Early diagnosis is critical for improving patient outcomes.
  • Lung cancer screening is an evolving field with significant potential.

Purpose of the Study:

  • To review current evidence on low-dose computed tomography (LDCT) for lung cancer screening.
  • To evaluate LDCT's impact on mortality reduction and discuss implementation.
  • To highlight emerging non-imaging biomarkers for lung cancer diagnosis.

Main Methods:

  • Review of existing literature on LDCT lung cancer screening.
  • Analysis of data on screening recommendations, eligibility, frequency, and duration.
  • Exploration of benefits, harms, and cost-effectiveness of LDCT screening.

Main Results:

  • LDCT screening in selected populations (age, smoking history) demonstrably reduces lung cancer mortality.
  • Optimization of target populations and LDCT protocols can enhance efficiency and cost-effectiveness.
  • Emerging non-imaging biomarkers show promise for future screening and diagnostic applications.

Conclusions:

  • LDCT screening is a proven method for reducing lung cancer mortality in at-risk individuals.
  • Further refinements in patient selection and LDCT management are needed.
  • Novel screening technologies and biomarkers represent future advancements in lung cancer detection.